Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 4, 2001, Pages 350-364

  Easterbrook, Philippa J ^a   Newson, Roger ^b   Ives, Natalie ^a   Pereira, Scott ^c   Moyle, Graeme ^c   Gazzard, Brian G ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

AIDS; Antiretroviral therapy; HIV; HIV RNA; Protease inhibitors; Treatment failure; Viral load

Indexed keywords

INDINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG CAPSULE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; TREATMENT FAILURE; UNITED KINGDOM; VIRUS LOAD;

EID: 0035424104     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200108010-00005     Document Type: Article

References (40)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
3. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
4. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
5. A randomised, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients: The INCAS trial
6. Update: Trends in AIDS incidence, deaths and prevalence - United States, 1996
7. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
8. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
9. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: Prospective multicentre study
10. Decline in deaths from AIDS due to new antiretrovirals
11. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
12. 3
13. The Atlantic Study: A randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen: 48 week data
14. Preliminary results of a randomized multicenter study comparing Combivir (ZDV/3TC) plus nelfinavir or nevirapine in HIV-infected naive patients
15. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
16. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
17. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort
18. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
19. Virological response to protease inhibitor therapy in an HIV clinic cohort
20. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
21. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
22. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons
23. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection
24. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study
25. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection
26. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: A randomised trial
27. A randomised clinical trial comparing a ritonavir/saquinavir vs an indinavir containing triple therapy regimen
28. Patients with plasma viral load (PVL) nadir 20-400 copies/ml on ZDV/ddI/NVP have shorter virologic suppression than patients on ZDV/3TC/indinavir or ZDV/3TC/nelfinavir
29. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: Selection of thymidine analog regimen therapy (START I)
30. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: Results from a community-based study
31. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment
32. Response to HAART in women, minorities and older patients: Results from the CHORUS HIV cohort study
33. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs
34. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
35. Maintenance antiretroviral therapies in HIV-infected patients with undetectable plasma HIV RNA after triple-drug therapy
36. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response
37. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
38. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
39. Research potentials and pitfalls in the use of an HIV clinical database: Chelsea and Westminster Hospital